针对免疫检查点抑制剂相关心房阻塞的节奏疗法:单中心队列研究
Jiaqi Wang1, Fanyi Kong2, Yifan Wang2
1Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China.
BMC cardiovascular disorders
|April 24, 2025
概括
节奏疗法对由免疫检查点抑制剂 (ICI) 引起的心房静脉阻塞 (AVB) 是安全有效的. 大多数ICI相关的AVB患者的导电恢复,使临时起器成为可行的初始治疗.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 免疫检查点抑制剂 (ICI) 相关心肌炎是一种罕见但严重的并发症.
- 房阻塞 (AVB) 可能发生在ICI相关的心肌炎中,通常需要节奏.
- 对ICI相关的AVB进行节奏治疗的疗效尚未得到充分证实.
研究的目的:
- 评估ICI相关的AVB患者的节奏治疗的安全性和有效性.
- 为了评估节拍后心房导的恢复率.
- 为了确定ICI相关AVB的最佳初始节奏策略.
主要方法:
- 对ICI相关心肌炎和需要节拍的AVB患者的回顾性研究.
- 评估基线特征和临时节奏疗法.
- 对生存和导电恢复的后续评估.
主要成果:
- 在43名ICI相关心肌炎患者中,11名 (25.6%) 患有先进或完整的AVB,需要节奏.
- 短期存活率为72.7% (8/11). 短时间存活率为72.7% (8/11).
- 在36.4% (4/11) 的患者中,心房导电恢复,没有复发. 节奏参数是可以接受的,其中有一次引领脱. 没有发生任何感染.
结论:
- 节奏治疗对于ICI相关的AVB是安全有效的.
- 与ICI相关的AVB具有很高的恢复率.
- 带有主动固定线的临时起器是合理的初始选择.
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
640
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
640
Heart Failure Drugs: β-Blockers
260
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
260
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
808
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
808
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.0K
Heart Failure Drugs: Inotropic Agents
405
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
405
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
680
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
680


